Anti-Jo-1 antibody positive polymyositis - Successful therapy with leflunomide

Autoimmunity

Volumn 39, Issue 3, 2006, Pages 261-264

  Lange, Uwe ^a   Piegsa, Manfred ^a   Müller Ladner, Ulf ^a   Strunk, Johannes ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Anti Jo 1 antibody; Dermatomyositis; Immunosuppressive therapy; Leflunomide; Polymyositis

Indexed keywords

ANTIBODY; AZATHIOPRINE; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; LEFLUNOMIDE; PREDNISOLONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE CONTROL; DRUG DOSE REGIMEN; FEMALE; FEVER; FREQUENCY ANALYSIS; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; MYOSITIS; PHYSICAL EXAMINATION; POLYARTHRITIS; POLYMYOSITIS; RAYNAUD PHENOMENON; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, ANTINUCLEAR; ARTHRITIS; AUTOANTIBODIES; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MIDDLE AGED; POLYMYOSITIS; PREDNISOLONE;

EID: 33745071200     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600623874     Document Type: Article

References (36)

1. Dalakas, MC. (2005) Autoimmune muscular pathologies Neurol Sci, 26(Suppl 1), pp. S7-S8.
2. Oddis, CV. (2005) Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies Curr Rheumatol Rep, 7, pp. 87-93.
3. Buchbinder, R and Hill, CL. (2002) Malignancy in patients with inflammatory myopathy Curr Rheumatol Rep, 4, pp. 415-426.
4. Targoff, IN. (2000) Update on myositis-specific and myositis-associated autoantibodies Curr Opin Rheumatol, 12, pp. 475-481.
5. Ranque-Francois, B and Maisonobe, T and Dion, E and Piette, JC and Chauveheid, MP and Amoura, Z and Papo, T. (2005) Familial inflammatory inclusion body myositis Ann Rheum Dis, 64, pp. 634-637.
6. Choy, EH and Hoogendijk, JE and Lecky, B and Winer, JB. (2005) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis Cochrane Database Syst Rev, 3, pp. CD003643.
7. Cannon, GW and Kremer, JM. (2004) Leflunomide Rheum Dis Clin North Am, 30, pp. 295-309.
8. Poor, G and Strand, V. (2004) Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: Multinational double-blind, randomized trial Rheumatology (Oxford), 43, pp. 744-749. Leflunomide Multinational Study Group.
9. Maddison, P and Kiely, P and Kirkham, B and Lawson, T and Moots, R and Proudfoot, D and (2005) Leflunomide in rheumatoid arthritis: Recommendations through a process of consensus Rheumatology (Oxford), 44, pp. 280-286.
10. Remer, CF and Weisman, MH and Wallace, DJ. (2001) Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study Lupus, 10, pp. 480-483.
11. Metzler, C and Fink, C and Lamprecht, P and Gross, WL and Reinhold-Keller, E. (2004) Maintenance of remission with leflunomide in Wegener's granulomatosis Rheumatology (Oxford), 43, pp. 315-320.
12. Eckhardt, SG and Rizzo, J and Sweeney, KR and Cropp, G and Baker, SD and Kraynak, MA and (1999) Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 (leflunomide) in patients with advanced solid tumours Clin Oncol, 17, pp. 1095- 1104.
13. Lakhanpal, S and Bunch, TW and Ilstrup, DM and Melton, LJ. (1986) Polymyositis-dermatomyositis and malignant lesions: Does an association exist Mayo Clin Proc, 61, pp. 645-653.
14. Serratrice, G and Schiano, A and Pellissier, JF and Pouget, J. (1986) 135 cases of polymyositis Rev Neurol, 142, pp. 906-917.
15. Lundberg and Chung, Y-L. (2000) Treatment and investigation of idiopathic inflammatory myopathies Rheumatol, 39, pp. 7-17.
16. Laxer, RM and Stein, LD and Petty, RE. (1987) Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis Arthritis Rheum, 30, pp. 328-334.
17. Oddis, CV and Medsger, TA. (1988) Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis J Rheumatol, 15, pp. 807-811.
18. Ramanan, AV and Campbell-Webster, N and Ota, S and Parker, S and Tran, D and Tyrrell, PN and (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids Arthritis Rheum, 52, pp. 3570-3578.
19. Metzger, AL and Bohan, A and Goldberg, IS and Bluestone, R and Pearson, CM. (1974) Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy Ann Intern Med, 81, pp. 182-189.
20. Sokoloff, MC and Goldberg, LS and Pearson, CM. (1971) Treatment of corticosteroid-resistant polymyositis with methotrexate Lancet, 1, pp. 14-16.
21. Bunch, TW. (1981) Prednisone and azathioprine for polymyositis Arthritis Rheum, 24, pp. 45-48.
22. Mehregan, DR and Su, WPD. (1993) Cyclosporine treatment for dermatomyositis/polymyositis Cutis, 51, pp. 59-61.
23. Lueck, CJ and Trend, P and Swash, M. (1991) Cyclosporin in the management of polymyositis and dermatomyositis J Neurol Neurosurg Psychiatry, 54, pp. 1007-1008.
24. Sinoway, PA and Callen, JP. (1993) Chlorambucil: An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis Arthritis Rheum, 36, pp. 319-324.
25. Bombardieri, S and Hughes, GRV and Neri, R. (1988) Cyclophosphamide in severe polymyositis Lancet, 1, pp. 1138-1139.
26. Kono, DW and Klashman, DJ and Gilbert, RC. (1990) Successful IV pulse cyclophosphamide in refractory PM in three patients with SLE J Rheumatol, 17, pp. 982-983.
27. Leroy, JP and Drosos, AA and Yiannopoulos, DI and Youinou, P and Moutsopoulos, HM. (1990) Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome Arthritis Rheum, 33, pp. 1579-1581.
28. Villalba, L and Hicks, JE and Adams, EM and Sherman, JB and Gourley, MF and Leff, RL and (1998) Treatment of refractory myositis. A randomised crossover study of two new cytotoxic regimens Arthritis Rheum, 41, pp. 392-399.
29. Cherin, P and Herson, S and Wechsler, B and Piette, JC and Bletry, O and Coutellier, A and (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients Am J Med, 91, pp. 162-168.
30. Cherin, P and Pelletier, S and Teixeira, A and Laforet, P and Genereau, T and Simon, A and (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis. An open study with 35 adult patients Arthritis Rheum, 46, pp. 467-474.
31. Dalakas, MC. (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis Neurology, 51, pp. 537-545.
32. Hachulla, E. (2001) Dermatomyositis and polymyositis: Clinical aspects and treatment Ann Med Interne (Paris), 152, pp. 455-464.
33. Migliorini, P and Baldini, C and Rocchi, V and Bombardieri, S. (2005) Anti-Sm and anti-RNP antibodies Autoimmunity, 38, pp. 47-54.
34. Ghirardello, A and Zampieri, S and Iaccarino, L and Tarricone, E and Gambari, PF and Doria, A. (2005) Anti-MI-2 antibodies Autoimmunity, 38, pp. 79-83.
35. Zampieri, S and Ghirardello, A and Iaccarino, L and Tarricone, E and Gambari, PF and Doria, A. (2005) Anti-JO-1 antibodies Autoimmunity, 38, pp. 73-78.
36. Spath, M and Schroder, M and Schlotter-Weigel, B and Walter, MC and Hautmann, H and Leinsinger, G and (2004) The long-term outcome of anti-Jo-1-positive inflammatory myopathies J Neurol, 251, pp. 859-864.